H.C. Wainwrigh on Kalvista Pharmaceuticals Inc (KALV): FY25 Ekterly revs show strong demand for HAE patients
Tweet Send to a Friend
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $37.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
